Sector Poised for a Turning Point,China Universal CSI Chinese Medicine ETF(560080) Rises 0.61% Intraday

NewTimeSpace News: As of 13:31 on March 24, 2026, the CSI Chinese Medicine Index (930641) rose 0.53%. Among its constituent stocks, Guizhou Xintian Pharmaceutical Co., Ltd. gained 3.69%, Henan Talong Pharmaceutical Co., Ltd. rose 2.68%, Darentang Group Co., Ltd. advanced 2.61%, Chongqing Huasen Pharmaceutical Co., Ltd. climbed 2.48%, and Zhejiang CONBA Pharmaceutical Co., Ltd. increased 2.46%. The China Universal CSI Chinese Medicine ETF(560080) rose 0.61% to a latest price of RMB 0.99. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

In terms of liquidity, the China Universal CSI Chinese Medicine ETFrecorded an intraday turnover rate of 1.36% with a trading volume of RMB 33.4126 million. Over a longer timeframe, as of March 23, the average daily trading volume of the China Universal CSI Chinese Medicine ETFstood at RMB 74.0485 million in the past year, ranking first among comparable funds.

In terms of scale, the China Universal CSI Chinese Medicine ETFsaw a notable growth of RMB 154 million in scale over the past year, with the newly added scale ranking in the top half among comparable funds. (Data source: Wind)

In terms of shares, the latest share count of the China Universal CSI Chinese Medicine ETFhit 2.488 billion shares, a new high in the past three months, ranking in the top 25% among comparable funds. (Data source: Wind)

In terms of capital inflows, the latest net capital inflow of the China Universal CSI Chinese Medicine ETFreached RMB 48.6982 million. Looking back, the ETF raked in a total of RMB 48.1335 million in the past five trading days. (Data source: Wind)

Data showed that leveraged funds have been continuously building positions in the ETF. The net margin purchase volume of the China Universal CSI Chinese Medicine ETFin the previous trading day reached RMB 5.5209 million, with the latest margin balance standing at RMB 66.2082 million. (Data source: Wind)

In terms of earnings capacity, as of March 23, 2026, since its inception, the China Universal CSI Chinese Medicine ETFhas achieved a maximum monthly return of 16.46%, a longest consecutive monthly gain streak of 5 months with a cumulative increase of 20.20% during the streak, and an average monthly return of 4.95% in positive months. As of March 23, 2026, the ETF has delivered an annualized excess return of 2.40% over the benchmark in the past two years, ranking in the top half among comparable funds.

In terms of drawdown, as of March 23, 2026, the maximum drawdown of the China Universal CSI Chinese Medicine ETFsince the start of the year was 9.02%, with a relative drawdown of 0.05% against the benchmark, indicating a low drawdown risk among comparable funds.

In terms of fees, the China Universal CSI Chinese Medicine ETFhas a management fee rate of 0.50% and a custodian fee rate of 0.10%, the lowest fee level among comparable funds.

In terms of tracking accuracy, as of March 23, 2026, the China Universal CSI Chinese Medicine ETFhad a tracking error of 0.008% in the past month, boasting the highest tracking accuracy among comparable funds.

From a valuation perspective, the latest price-to-earnings ratio (PE-TTM) of the CSI Chinese Medicine Index tracked by the China Universal CSI Chinese Medicine ETFwas only 22.06 times, at the 0.39% quantile of the past year. That is, the valuation was lower than that in more than 99.61% of the time over the past year, standing at a historical low.

The China Universal CSI Chinese Medicine ETFclosely tracks the CSI Chinese Medicine Index, which selects securities of listed companies engaged in the production and sales of Chinese medicine and related businesses as index samples to reflect the overall performance of listed companies with Chinese medicine concepts.

Data showed that as of February 27, 2026, the top 10 weight stocks of the CSI Chinese Medicine Index (930641) were Yunnan Baiyao Group Co., Ltd., Zhangzhou Pientzehuang Pharmaceutical Co., Ltd., Shandong Dong'e Ejiao Co., Ltd., Tongrentang Group Co., Ltd., China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., Jilin Aodong Pharmaceutical Group Co., Ltd., Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd., Shijiazhuang Yiling Pharmaceutical Co., Ltd., Zhuhai Zhongshan Pharmaceutical Co., Ltd. and Darentang Group Co., Ltd. in sequence, with the combined weight of the top 10 stocks accounting for 55.23%. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

Huafu Securities stated that in February 2026, the National Health Commission and 10 other competent departments revised the Administrative Measures for the National Essential Drugs List. Following the release of the new list, the "986" allocation policy is expected to be implemented more clearly, further boosting the sales volume of essential drug varieties. Currently, the Chinese medicine sector is still undervalued and under-allocated, and is poised to usher in a turning point against the backdrop of policy catalysis, falling prices of medicinal materials and inventory clearance.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.